BioSpace News Archive

Beacon Therapeutics launches with £96 million ($120 million) to develop a new generation of gene therapies for retinal diseases resulting in blindness

Beacon Therapeutics Holdings Limited, a leading ophthalmic gene therapy company with a purpose to restore and improve the vision of patients with retinal diseases, launches and will develop a new generation of gene therapies to treat a range of rare and prevalent retinal diseases that result in blindness.

June 12, 2023
·
7 min read
Drug Development

Oxurion Finalizes Enrollment in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema

Oxurion NV announced that it has randomized the last patient in its KALAHARI Phase 2, Part B clinical trial for diabetic macular edema .

June 12, 2023
·
5 min read
Business

Metrion Biosciences appoints Dr Steve Jenkinson as VP, Drug Discovery and Safety Assessment to strengthen US operations

Metrion Biosciences Ltd, the specialist ion channel contract research and drug discovery company, announced the appointment of Dr Steve Jenkinson as Vice President, Drug Discovery and Safety Assessment.

June 12, 2023
·
2 min read
Drug Development

IDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP-Deletion Solid Tumor Types

IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced selection of a monotherapy expansion dose for the Phase 2 clinical trial evaluating IDE397 in patients having solid tumors with MTAP deletion.

June 12, 2023
·
5 min read
Policy

Indivior to Commence Trading on Nasdaq

Indivior PLC announces that the U.S. Securities & Exchange Commission declared its registration statement on Form 20-F effective on June 9.

June 12, 2023
·
6 min read
Pharm Country

Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®

Alvotech and Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced they have reached a settlement and license agreement with Johnson & Johnson concerning AVT04, Alvotech’s proposed biosimilar to Stelara® in the United States.

June 12, 2023
·
11 min read
Policy

US FDA Grants for Over-the-Counter Marketing Authorization to Futura for Fast-Acting Topical Gel, MED3000, to Treat Erectile Dysfunction

Futura Medical plc announces that the US Food and Drug Administration has granted over the counter sale Marketing Authorisation for MED3000, the Company’s breakthrough, topical gel formulation for the treatment of erectile dysfunction as a De Novo Medical Device.

June 12, 2023
·
4 min read